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 Abstract - T-large granular lymphocyte 
leukemia (T-LGLL) is a chronic clonal proliferation 
of effector memory cytotoxic CD3+CD57+CD56- T 
cells and the current guidelines suggest 
immunosuppressive therapy as first-line therapy, but 
the treatment of refractory/relapsed patients is still 
challenging due to the lack of prospective studies.  
We describe a series of two refractory/relapsed 
T-LGLL patients successfully treated with 
bendamustine, a chemotherapeutic agent largely used 
for B-cell neoplasms, but poorly investigated for the 
treatment of T-cell diseases. Complete remission 
(CR) was achieved in 3 and 6 months, respectively, 
and maintained for at least 20 months. One patient 
relapsed after a 20-month CR, but she was 
responsive to bendamustine therapy again, obtaining 
a further prolonged CR.  
Bendamustine as single agent or in combination 
could be a feasible therapeutic option in 
refractory/relapsed T-LGLL, especially for elderly 
patients because of its safety profile.  
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I.  INTRODUCTION 
 
 Large granular lymphocyte leukemias (LGLL) 
are chronic clonal lymphoproliferations of mature post-
thymic TCRαβ+ CD3+CD4-CD5dimCD8+CD27-CD28-
CD45RO-CD57+ T cells (T-LGLL, 85% of cases) or CD3-
CD56+ natural killer cells (NK-LGLL) [1-5]. T-LGLL 
usually affects old subjects (> 60 years) with an indolent 
course and a median overall survival > 10 years [1,5]. At 
diagnosis, T-LGLL patients show peripheral blood (PB) 
cytopenias, splenomegaly, bone marrow (BM) infiltration 
by clonal large granular lymphocytes (LGLs), frequently 
associated with autoimmune or hematologic disorders 
(40% of cases) (Table 1) [1,3,5]. 
Current guidelines of T-LGLL suggest to start               
treatment  only in patients with symptomatic  or life- 
threatening  cytopenias (Table 2) [3,4]. Immuno- 
suppressive therapy (IST), with single agent methotrexate 
(MTX), cyclophosphamide (CTX), or cyclosporin-A 
(CyA), is the first-line therapy of T-LGLL. 
 
Table 1. LGLL diagnostic criteria  [3,5] 
 Clinical presentation: 
PB cytopenia(s)  
Splenomegaly 
Autoimmune diseases 
 LGL > 0.5 x 109 cells/L  
 LGL morphology: 
Large dimensions (15-18 um of diameter) 
Round or reniform nucleus 
Abundant cytoplasm with azurophilic granules  
 LGL phenotype:  
T: TCRαβ+CD3+CD4-CD5dimCD8+CD27-CD28-CD45RO-CD57+ 
NK: CD3-CD16+CD56+CD57+  
 Presence of clonal TCR rearrangement by PCR or flow cytometry 
Abbreviations. LGLL = large granular lymphocyte leukemia; PB = 
peripheral blood; LGL = large granular lymphocytes; TCR = T cell 
receptor; NK = natural killer cell; PCR = polymerase chain reaction. 
 
Overall response rate with IST ranges from 40% to 70%, 
but no standard treatments are clearly defined due to the 
lack of prospective studies [3-5].  Relapsed patients after  
IST stop or tapering, as defined in Table 3, are eligible for 
a second course of immunosuppression with similar or 
different IST [6]. In T-LGLL patients with IST failure 
after 4 months, a switch to a second-line treatment is 
recommended [5,7]. Bendamustine is an alkylating agent 
that may act as a purine analogue, but the precise 
mechanism of action is still unclear [8]. This drug is 
largely used in B-cell non-Hodgkin lymphoma (NHL), but 
recent studies have focused on refractory/relapsed T cell 
neoplasm patients, suggesting a role of this drug also in T-
cell NHL [9-10].  
Here, we report two cases of elderly refractory T-
LGLL patients who achieved a prolonged complete 
remission using bendamustine as salvage therapy. 
 
Table 2. Treatment indications in LGLL [3,5] 
 Severe neutropenia (absolute neutrophil count <0.5 x109 cells/L) 
 Moderate neutropenia (absolute neutrophil count <1 x109 cells/L) with 
recurrent infections 
 Symptomatic or transfusion dependent anemia 
 Severe thrombocytopenia (<0.5 x 109/L)  
 Associated autoimmune conditions requiring therapy 
Abbreviations. LGLL = large granular lymphocyte leukemia. 
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II.  PATIENTS AND METHODS 
 
 In this study, two T-LGLL patients were enrolled 
after informed consent in accordance with the Declaration 
of Helsinki [11] and the institutional review boards of the 
Hematology and Transplant Center, Department of 
Medicine and Surgery, University of Salerno, Italy. The 
authors retrospectively reviewed all available medical 
records.  
 
Table 3. Response criteria in LGLL [3] 
 Complete response: 
Hemoglobin >12 g/dL  
Platelet count ≥150 x 109/L  
ANC  >1.5 x 109 cells/L 
ALC <4 x 109 cells/L with circulating LGLs < 0.5 x 109 cells/L 
 Partial response: 
Improvements of blood count that do not meet criteria for CR 
ANC >0.5 x109 cells/L or decreasing transfusion requirements 
 Treatment failure: 
Failure to achieve partial or complete response 
 Progressive disease: 
Worsening of cytopenias, hepatomegaly or splenomegaly 
Abbreviations. LGLL = large granular lymphocyte leukemia; 
ANC = Absolute neutrophil count;  ALC = Absolute lymphocyte count;  
LGLs = large granular lymphocytes; CR = complete remission. 
 
 
III.  RESULTS 
 
Case 1  
A 73-year-old woman received diagnosis of T-
LGLL in 2003 from other institution. Treatment with low-
dose oral MTX, (10 mg/m2 weekly) and prednisone 
(PDN) was started in 2008, due to anemia and moderate 
thrombocytopenia. After a 4-month therapy, in the 
absence of a clinical response, oral CTX (100 mg/day)  
and PDN for 4 months were used as second-line treatment 
without any response, although this therapy was 
associated with erythropoiesis-stimulating agents (ESAs). 
In August 2012, the patient referred to our institution for 
fatigue, transfusion-dependent severe anemia and 
neutropenia. The basic clinical characteristics, laboratory 
data on admission and clinical records of the patient are 
detailed in Table 4. 
 In September 2012, oral CyA, (2 mg/Kg/day) 
and PDN were administered as third-line therapy, but the 
patient experienced the worsening of cytopenias, the 
increase in the transfusion support (8-10 packed red blood 
cell transfusions/month), and positivity of indirect and 
direct antiglobulin tests. After 8 months of no clinical 
response, the patient performed a salvage therapy with 
bendamustine (70 mg/m2 for 2 consecutive days every 28 
days). Pneumocystis jiroveci prophylaxis was carried out 
with trimethoprim/sulfamethoxazole (TMP/SMX), while 
ESAs were administered to improve erythropoiesis. After 
the first bendamustine course, our patient experienced a 
rapid hemoglobin improvement and transfusion 
independence, achieving complete remission (CR) within 
three months. Grade 4 neutropenia was documented after 
the second course of chemotherapy and treated with 
granulocyte colony-stimulating factors (G-CSFs). The 
patient experienced also other complications such as 
Escherichia coli-related urinary tract infection (treated 
with 500 mg/day oral levofloxacin for 6 days) and 
hypertransaminasemia associated with vasculitis-like rush 
of the limbs after the third cycle, which led to the 
treatment discontinuation  and patient re-evaluation. 
Given that the patient was in CR and showed a minimal 
BM infiltration (LGLs <10% of total cellularity), 
bendamustine was definitely discontinued. CR was 
maintained for 20 months, when the patient showed again 
anemia; for this reason, a second course of 4 cycles of 
bendamustine was administered, without any clinical 
toxicity. At last follow-up, 12 months after the end of 
therapy, the patient was still in CR. 
 
Case 2  
A 72-year-old man was admitted to our 
department in October 2013 for severe anemia associated 
with atypical circulating and marrow LGLs (Figure 1A). 
Physical examination did not detected lymphadenopathies 
and hepatomegaly, but revealed splenomegaly, confirmed 
by ultrasonography (longitudinal diameter, 150 mm; 
anteroposterior diameter, 156 mm; transverse diameter, 66 
mm). Other clinical characteristics, laboratory data on 
admission and clinical records of the patient are 
summarized in Table 4. Immunosuppression was started 
with CyA (5 mg/Kg/day) and PDN (0.5 mg/kg/day). After 
a 4-month therapy, the persistence of transfusion-
dependent anemia and the worsening of neutropenia (0.29 
x 109 cells/L) required a second line therapy. 
Bendamustine was administrated for a total of 6 cycles at 
70 mg/m2 for 2 days every 28 days. Bacterial, fungal and 
Pneumocystis jiroveci prophylaxis was carried out using 
oral levofloxacin (500 mg/day), oral fluconazole (200 
mg/day), and TMP/SMX (160-800 mg/twice per week). 
ESAs and G-CSFs were also administered to reduce 
myelosuppression and to prevent febrile neutropenia. 
Grade 3 neutropenia and two episodes of transient 
hypertransaminasemia with indirect hyperbilirubinemia 
were documented, but they did not require drug 
discontinuation. CR was achieved after 6 cycles of 
bendamustine and, after that, the patient no longer needed 
transfusions or ESAs administration (Figure 1B). BM 
aspiration performed at the end of treatment did not show 
evidence of lymphoproliferative disorder, confirmed by 
BM flow cytometry immunophenotype and BM biopsy. 
After 26-month of follow-up, the patient was still in CR. 
 
IV.  DISCUSSION 
 
T-LGLL is a chronic lymphoproliferative 
disorder with an indolent course, mostly diagnosed after 
the sixtieth decade of life1. T-LGLL patients are a fragile 
population because of their older age (>60-year-old), the 
presence of comorbidities (frequently autoimmune 
disorders) and symptoms which   negatively  influence the  
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Table 4. Patients characteristics  
 Case 1 Case 2 
 Age 73 72 
 Sex Female Male 
 Laboratory data on admission 
Hemoglobin g/dL 
White blood cell (x 109 cells/L) 
Absolute lymphocyte count (x 109 cells/L) 
Absolute neutrophil count (x 109 cells/L) 
Platelet count (x 109cells/L)  
Mean corpuscular volume (fL) 
Lactate dehydrogenase (U/L) 
Rheumatoid factor 
Anti-nuclear antibodies titer 























 Peripheral blood LGLs 
Percentage (%) 










 Indications for treatment Transfusion dependent anemia Transfusion dependent anemia, splenomegaly 
 Immunosuppressive therapies  MTX+ PDN, CTX+PDN, CyA+ PDN CyA+PDN 
 Response to  immunosuppressive  therapies  Treatment failure Treatment failure 
 Time to-BENDA treatment  10 years 4 months 
 BENDA dosage     70 mg/m2 for 2 days every 28 days                       70 mg/m2 for 2 days every 28 days 
 Number of BENDA cycles  3 and 4* 6 
 Response to BENDA Complete response Complete response 
 Follow up (months) after BENDA treatment 20 and 12° 26 
Abbreviations. n.e. = not evaluated; LGLs = large granular lymphocytes; MTX = methotrexate; PDN = prednisone; CTX = cyclophosphamide;    
CyA = cyclosporine-A; BENDA = bendamustine.   
Symbols. * = 3 cycles of BENDA and 4 after relapse; ° = 20 months after first BENDA treatment and 12 after the second BENDA treatment. 
 
quality of life and the outcome [12,13]. Nowadays, there 
are no “curative” therapeutic options for T-LGLL. For this 
reason, the goals are the stabilization of the disease and 
the correction of cytopenias. IST is the mainstay of 
treatment for T-LGLL [3,5], but the optimal therapeutic 
strategy for refractory/relapsed patients is still 
challenging, even though purine analogues and 
alemtuzumab are currently used as second-line therapy4.  
Bendamustine, a molecule developed more than 
50 years ago, is an alkylating agent with a complex 
mechanism of action, sharing characteristics with purine 
analogues [8,11]. Several mechanisms of action have been 
hypothesized, as the induction of extensive and durable 
DNA damage and impairment of DNA repair [8]. The 
inhibition of the DNA repair mechanism could be 
enhanced by the in vitro combination of bendamustine 
with cladribine or fludarabine, commonly used for B-cell 
and T-cell NHL [8,14]. Bendamustine can induce 
apoptosis through traditional and non-traditional pathways 
[8]. In particular, the activation of mitotic catastrophe is 
caspase-2-dependent and cannot be inhibited by 
overexpression of Bcl-2 [8]. Moreover, the p53-dependent 
DNA-damage response pathways can be activated not 
only by bendamustine-induced DNA interstrand 
crosslinks, but also by oxidative stress and increased 
release of apoptosis-inducing factor from mitochondria 
[8]. Based on the interesting results of Zaja et al. in 2013 
in a small cohort of T-cell NHL refractory/relapsed 
patients, we decided to start bendamustine administration 
in two cases of refractory T-LGLL patients, according to 
the dosage previously reported [9]. Furthermore, 
bendamustine was chosen as salvage therapy due to its 
mechanism of action, hypothesizing that the mitotic 
catastrophe could avoid the constitutively activated anti-
apoptotic pathways in LGLs [8]. Indeed, our series of 
refractory T-LGLL patients experienced a rapid clinical 
response and achieved the CR within 3 and 6 months, 
respectively. One patient relapsed after 20 months of CR 
with a minimal BM LGL infiltration. Interestingly, she 
was still responsive to a second course of bendamustine 
which allowed a 12-months disease-free survival at the 
time of writing. Moreover, bendamustine was confirmed 
as a drug with a good safety profile [14], because the 
myelosuppression was easily managed with G-CSFs and 
ESAs. 
 
V.  CONCLUSION 
 
Standard salvage treatment for 
relapsed/refractory T-LGLL patients has not been defined 
yet due to the lack of prospective studies. Bendamustine-
based regimens are increasingly used in both B-cell and T 
cell neoplasms, but few studies are available for T-LGLL. 
Our case series shows the efficacy and safety of 
bendamustine in the treatment of elderly 
relapsed/refractory T-LGLL patients. Even though these 
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results require further validation in prospective 
randomized studies, bendamustine as single agent or in 
combination should be considered a feasible second-line 
option for relapsed or refractory T-LGLL. 
 
 
Figure 1. Bone marrow morphological features and clinical course in 
case 2 T-LGLL. 
(A) Marrow large granular lymphocytes with abundant cytoplasm and 
the characteristic azurophilic granules (May–Giemsa assay, Nikon 
Microscope, Ci-L model; original magnification 20X left panel, and 
100X right panel). 
 (B) Hemoglobin levels during and after bendamustine treatment.  Red 
blood cell transfusions are displayed as dark red arrow, according to the 
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